Daré Bioscience, Inc. Appoints Mary Jarosz, Rph, to the Newly Created Role of Global Head of Regulatory Affairs
June 04, 2018 at 08:00 am
Share
Daré Bioscience, Inc. announced the appointment of Mary Jarosz, RPh, to the newly created role of Global Head of Regulatory Affairs. Ms. Jarosz has over 20 years of experience in the pharmaceutical industry. Prior to her appointment as Global Head of Regulatory Affairs, Ms. Jarosz served as the Senior Vice President of Regulatory Affairs & Quality Assurance at Evofem Biosciences.
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
DARÉ BIOSCIENCE, INC. 
